Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FL-101 in Non-Metastatic Muscle Invasive Bladder Cancer
NCT05395260Phase 1Withdrawn
- Sponsor
- Flame Biosciences
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of abdakibart in muscle-invasive bladder cancer (MIBC), sponsored by Flame Biosciences. Primary endpoint: Effect of FL-101 on CRP. Planned start Aug 2022; status: withdrawn.
02
Drugs
abdakibart
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT05395260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05395260.